Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report

Gastric neuroendocrine tumors (g-NETs) are classified into: Type 1, associated with chronic atrophic gastritis (CAG); Type 2, related to Zollinger–Ellison Syndrome/Multiple Endocrine Neoplasia Type 1; and sporadic Type 3 . Type 1, the most common, typically presents as small, well-differentiated tumors with excellent survival . Tumor size and gender are important prognostic factors in Type 1 g-NETs, with a controversial prognostic role of the Ki-67 index . Metastatic Type 1 g-NETs are rare and treatment of advanced cases mirrors that of other advanced NETs, including somatostatin analogs (SSA) and peptide receptor radionuclide therapy (PRRT), though specific data are limited